DNA X Stock Looks at Nasdaq Deadline After Latest Financing
DNA X said Nasdaq will delist its shares after the company fell short of stockholders’ equity rules, posting a $983,000 deficit for the March quarter. The company plans to request a hearing by May 29 to halt suspension as it appeals. DNA X shares last traded at $4.07 in premarket, valuing the firm at about $5.1 million. The company also announced a $3.05 million convertible note financing.